Acta Med Port 2017 06 30;30(6):429-430. Epub 2017 Jun 30.
Diretor Clínico. APDP - Associação Protetora dos Diabéticos de Portugal. Lisboa. Portugal.; Professor Auxiliar Convidado. Nova Medical School. Lisboa. Portugal.
Download full-text PDF
Diabet Med 2012 Feb;29(2):198-206
Family Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Aims: The aim was to evaluate treatment goal achievements early in the course of Type 2 diabetes, and their effect on 10-year risk of coronary heart disease in patients receiving usual care.
Methods: Assessment of risk factor control 3 years after diagnosis in patients with Type 2 diabetes with no previous coronary heart disease included from the Swedish National Diabetes Register; a total of 19,382 patients (mean age 58 years) in cross-sectional surveys from 2003 to 2008, and a subgroup of 4293 patients followed individually from year of diagnosis to follow-up after a mean 2.6 years. Read More
PLoS One 2009 Nov 17;4(11):e7697. Epub 2009 Nov 17.
Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
Background: TCF7L2 polymorphisms have been consistently associated with type 2 diabetes mellitus in different populations and type 2 diabetes mellitus is a major risk factor for cardiovascular disease, especially coronary artery disease. This study aimed to evaluate the association between TCF7L2 polymorphism rs7903146 and coronary artery disease in diabetic and non-diabetic subjects.
Methods And Results: two populations were studied in order to assess severity of coronary artery disease and cardiovascular events incidence. Read More
J Manag Care Pharm 2007 Oct;13(8):652-63
Merck and Co., Inc., 770 Broad Street, West Point, PA, USA.
Background: Patients beginning treatment with lipid-modifying drugs should have their serum lipid levels monitored and, if necessary, their drug therapy adjusted to reach and maintain their treatment goals. Patients with coronary heart disease or diabetes are at high risk of coronary events and are particularly important target groups for monitoring and dose adjustment of lipid-modifying drug therapy.
Objective: to determine from administrative claims the rates of lipid testing, treatment with low-density lipoprotein cholesterol (LDL-C)-lowering drug therapy, and LDL-C goal attainment defined as LDL-C < 100 mg per DL in the time period after a new diagnosis of coronary heart disease or diabetes among patients who had not previously received lipid-modifying drug therapy. Read More
Cardiovasc Diabetol 2006 Jul 17;5:15. Epub 2006 Jul 17.
Faculty of Medicine, Tehran University of Medical Sciences, Keshavarz Blvd, Tehran, Iran.
Background: Coronary artery disease is the leading cause of death in industrialized countries and most patients with diabetes die from complications of atherosclerosis. The objective of this study was to determine the presence of diabetes mellitus and other conventional coronary heart disease risk factors (cigarette smoking, hypertension and hyperlipidemia) in patients with acute coronary events in an Iranian population.
Methods: The study included 514 patients with unstable angina or myocardial infarction (MI) out of 720 patients admitted to CCU ward of a general hospital from March 2003 to March 2005. Read More